Complete remission achieved in a case of both primary and recurrent adult acute myelogeneous leukemia by a novel nutritional therapy.
The aim of this study was to determine the possible clinical benefit of molasses-based dietary compositions (designated as MSQ 13, MSQ 15, and MSQ 18) in a case of both primary and recurrent adult AML. The design was a single case study. The setting was in the home. The regime of dietary compositions initially was administered as follows: MSQ-13 1 tbsp t.i.d. for 1 mo, MSQ-15 2 tbsp t.i.d. for 3 mo. After recurrence, MSQ-18 was taken at 2 tbsp t.i.d. for 3 mo. Clinical improvement and regression of AML were the outcome measures. Treatment with the MSQ dietary compositions resulted in disease regression and the reversal of clinical manifestations over two episodes of AML. Therefore, further studies are warranted to evaluate the utility of this approach for the clinical management of AML.